/
DYN
$18.55+$0.31 (+1.70%)live
Change+$2.42
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$3.4B
187M shares
52-week range
$11.92 – $27.31
43% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Dyne Therapeutics, Inc. Common Stock
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
www.dyne-tx.com- Employees
- 258
- IPO / List date
- Sep 17, 2020
- HQ
- WALTHAM, MA
Held by traders on TradeandTell
No one on the platform currently holds DYN.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 533,600 | $9.7M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded DYN yet.
